A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors
NCT02129205
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
40
Enrollment
INDUSTRY
Sponsor class
Stopped
The study was terminated due to a change in sponsor prioritization.
Conditions
Neoplasms
Breast Cancer
Interventions
DRUG:
PF-06650808
DRUG:
PF-06650808
Sponsor
Pfizer